Insider Selling: NewAmsterdam Pharma (NASDAQ:NAMS) CAO Sells 34,400 Shares of Stock

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) CAO Louise Frederika Kooij sold 34,400 shares of the company’s stock in a transaction that occurred on Monday, January 26th. The stock was sold at an average price of $32.78, for a total value of $1,127,632.00. Following the transaction, the chief accounting officer directly owned 24,353 shares of the company’s stock, valued at approximately $798,291.34. The trade was a 58.55% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Louise Frederika Kooij also recently made the following trade(s):

• On Friday, January 23rd, Louise Frederika Kooij sold 38,172 shares of NewAmsterdam Pharma stock. The stock was sold at an average price of $33.75, for a total value of $1,288,305.00.
• On Monday, January 5th, Louise Frederika Kooij sold 2,647 shares of NewAmsterdam Pharma stock. The stock was sold at an average price of $33.25, for a total transaction of $88,012.75.
• On Friday, December 26th, Louise Frederika Kooij sold 43,872 shares of NewAmsterdam Pharma stock. The shares were sold at an average price of $35.30, for a total transaction of $1,548,681.60.
• On Tuesday, December 23rd, Louise Frederika Kooij sold 75,117 shares of NewAmsterdam Pharma stock. The shares were sold at an average price of $36.21, for a total value of $2,719,986.57.
• On Wednesday, December 24th, Louise Frederika Kooij sold 26,011 shares of NewAmsterdam Pharma stock. The stock was sold at an average price of $35.68, for a total transaction of $928,072.48.

NewAmsterdam Pharma Price Performance

Shares of NAMS stock traded up $0.26 on Tuesday, hitting $32.63. The stock had a trading volume of 421,344 shares, compared to its average volume of 750,314. The firm has a market capitalization of $3.70 billion, a P/E ratio of -15.92 and a beta of 0.07. NewAmsterdam Pharma Company N.V. has a 1 year low of $14.06 and a 1 year high of $42.00. The company’s 50 day moving average price is $35.58 and its 200-day moving average price is $31.17.

NewAmsterdam Pharma (NASDAQ:NAMS) last issued its quarterly earnings results on Wednesday, November 5th. The company reported ($0.41) earnings per share for the quarter, missing the consensus estimate of ($0.38) by ($0.03). NewAmsterdam Pharma had a negative return on equity of 28.30% and a negative net margin of 627.59%.The company had revenue of $0.35 million for the quarter, compared to analysts’ expectations of $4.54 million. On average, equities analysts forecast that NewAmsterdam Pharma Company N.V. will post -1.75 EPS for the current year.

Institutional Investors Weigh In On NewAmsterdam Pharma

A number of institutional investors have recently modified their holdings of NAMS. Capital World Investors increased its position in NewAmsterdam Pharma by 17.1% in the third quarter. Capital World Investors now owns 9,822,711 shares of the company’s stock worth $279,358,000 after buying an additional 1,434,986 shares during the period. Jennison Associates LLC raised its position in shares of NewAmsterdam Pharma by 42.5% during the 3rd quarter. Jennison Associates LLC now owns 4,198,554 shares of the company’s stock worth $119,407,000 after buying an additional 1,252,451 shares in the last quarter. Duquesne Family Office LLC lifted its position in NewAmsterdam Pharma by 131.2% in the third quarter. Duquesne Family Office LLC now owns 1,923,700 shares of the company’s stock worth $54,710,000 after purchasing an additional 1,091,525 shares during the period. Adage Capital Partners GP L.L.C. raised its position in NewAmsterdam Pharma by 54.5% in the second quarter. Adage Capital Partners GP L.L.C. now owns 3,013,009 shares of the company’s stock worth $54,566,000 after acquiring an additional 1,062,359 shares in the last quarter. Finally, Maverick Capital Ltd. increased its holdings in shares of NewAmsterdam Pharma by 178.8% in the second quarter. Maverick Capital Ltd. now owns 1,531,874 shares of the company’s stock valued at $27,742,000 after buying an additional 982,405 shares in the last quarter. Institutional investors own 89.89% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on NAMS. Leerink Partners reissued an “outperform” rating and issued a $55.00 target price on shares of NewAmsterdam Pharma in a report on Tuesday, January 6th. Royal Bank Of Canada boosted their price target on NewAmsterdam Pharma from $44.00 to $47.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 21st. The Goldman Sachs Group lifted their target price on shares of NewAmsterdam Pharma from $30.00 to $37.00 and gave the stock a “neutral” rating in a research report on Tuesday, December 2nd. HC Wainwright began coverage on NewAmsterdam Pharma in a research report on Monday, October 20th. They issued a “buy” rating and a $52.00 price objective on the stock. Finally, Needham & Company LLC raised their price objective on NewAmsterdam Pharma from $40.00 to $46.00 and gave the stock a “buy” rating in a report on Wednesday, November 5th. Nine analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, NewAmsterdam Pharma currently has an average rating of “Moderate Buy” and a consensus target price of $47.00.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation.